Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

 Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025

Vinge has advised EQT AB in connection with its bond issue in the aggregate principal amount of USD 500,000,000

 EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an interest rate of 5.850%, due 2035, at a price equal to 99.783% of the aggregate principal amount thereof.
May 13, 2025

Vinge has advised Qlik in connection with acquisition

 Vinge has advised the Qlik Group in connection with its acquisition of the Qloud Cover Migration technology from Stretch Qonnect. This automated solution, to be branded as the Qlik Analytics Migration Tool, eliminates the complexity of migrating from QlikView, Qlik Sense, and NPrinting to Qlik Cloud – a persistent barrier to cloud adoption.
May 13, 2025